Network Data and Analysis Will Greatly Enhance Patient Safety and Reduce Healthcare Costs
BETHESDA, Md., July 16 /PRNewswire-USNewswire/ -- The U.S. Biovigilance Network, the nation's first and only nationwide data collection program for the transfusion and biological therapy communities, is preparing for a fall 2008 launch of its pilot. The Network has raised more than $1 million in private donations, including an $84,000 contribution by Fenwal Inc., one of the community's medical technology leaders. It has also secured support from hospitals and blood centers across the country.
The Network is a unique public/private collaboration with shared responsibilities for program development, operation and management, and funding. The federal government, through the Department of Health and Human Services, including the Centers for Disease Control and Prevention, has provided the platform for initial surveillance efforts through its National Healthcare Safety Network. The U.S. Biovigilance Network has raised $1 million in private contributions to fund the initial expenses and is seeking $2 million in additional support to complete development and implement the program.
"To ensure the safety of America's blood supply, it is vital that we create a centralized and standardized process for reporting adverse events," said Barbee Whitaker, Ph.D., AABB's Director of Data and Special Programs. "With data from the U.S. Biovigilance Network, we will be able to create a quality system that benefits patients, donors and the public health of the U.S."
The U.S. Biovigilance Network will, for the first time on a nationwide
basis, collect and analyze data to identify trends and recommend best
practices to reduce adverse reactions and incidents associated with blood
transfusion and related biological therapies. Ultimately, the analyses of
these data will enhance patient safety, make better use of blood and
biological therapies, and reduce healthcare cos
'/>"/>
| SOURCE AABB Copyright©2008 PR Newswire. All rights reserved |